Cybin Inc. Common Stock
HELP
Rangering i aksjer
#11651
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Aksjekurs
$10.30
Sist synkronisert: 2026-08-11
Markedsverdi
$638.32M
Endring (1 dag)
2.88%
Endring (1 år)
9,119.52%
Land
CA
Handel Cybin Inc. Common Stock (HELP)
Kategori
Healthcare
P/B-forhold for Cybin Inc. Common Stock (HELP)
P/B-forhold per 2026 TTM: 0
Ifølge Cybin Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Cybin Inc. Common Stock fra 2026 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
